Von Hippel-Lindau Disease

1. Disease Information

1.1 Definition/overview

VHL disease is a rare, inherited tumor predisposition syndrome characterized by development of benign and malignant tumors and cysts across multiple organs (CNS, retina, kidneys, pancreas, adrenals, and others). (gomezvirgilio2024geneticspathophysiologyand pages 1-2, kaelin2022vonhippel–lindaudisease pages 1-2)

1.2 Key identifiers (as explicitly available in retrieved sources)

• OMIM (disease): Von Hippel-Lindau syndrome OMIM #193300 (alvarez2024germlinevariantsin pages 1-2)
• OMIM (gene): VHL tumor suppressor gene OMIM *608537 (alvarez2024germlinevariantsin pages 1-2)
• ICD-10: Q85.83 (as used to define a cohort in a TriNetX real-world analysis) (hochberg2024isthetrinetx pages 1-2)

Not available from the retrieved evidence excerpts: Orphanet ORPHA code, MeSH unique ID, MONDO ID, ICD-11 code. These would normally be sourced from Orphanet/MeSH/MONDO directly, but they were not present in the accessible text segments used here (alvarez2024germlinevariantsin pages 1-2, gomezvirgilio2024geneticspathophysiologyand pages 1-2, hochberg2024isthetrinetx pages 1-2).

1.3 Synonyms/alternative names

Explicitly used name variants in retrieved sources include: - “Von Hippel–Lindau disease” / “von Hippel–Lindau (VHL) disease” / “VHL disease” / “VHL” (gomezvirgilio2024geneticspathophysiologyand pages 1-2) - “Von Hippel-Lindau syndrome” / “VHL syndrome” (alvarez2024germlinevariantsin pages 1-2) - “Von Hippel–Lindau (vHL) disease” / “vHL” (hochberg2024isthetrinetx pages 1-2)

1.4 Evidence provenance

The report synthesizes aggregated disease-level reviews (e.g., 2024 Diagnostics review; 2022 JCI review) and primary/real-world studies (claims-based epidemiology; clinical trial report; cohort analyses). (jonasch2024epidemiologyandeconomic pages 1-2, else2024belzutifanforvon pages 5-6, gomezvirgilio2024geneticspathophysiologyand pages 1-2, kaelin2022vonhippel–lindaudisease pages 1-2, zhang2024vonhippellindau pages 1-2)

2. Etiology

2.1 Disease causal factors

• Primary cause: Germline pathogenic variants in VHL, consistent with autosomal-dominant tumor predisposition; pVHL is a tumor suppressor that regulates HIFα stability via a Cullin2-based E3 ubiquitin ligase complex. (gomezvirgilio2024geneticspathophysiologyand pages 1-2, kaelin2022vonhippel–lindaudisease pages 1-2)
• Mechanistic core: Under normoxia, prolyl hydroxylases (PHD/EglN family) hydroxylate HIFα, enabling pVHL recognition and proteasomal degradation; VHL loss leads to HIF accumulation and transcriptional activation of pro-tumor programs. (gomezvirgilio2024geneticspathophysiologyand pages 11-13, kaelin2022vonhippel–lindaudisease pages 1-2)

2.2 Risk factors

• Genetic: Carrying a germline VHL pathogenic variant is the dominant risk factor; penetrance of manifestations is reported as ~97% by age 65 in a 2024 review. (gomezvirgilio2024geneticspathophysiologyand pages 1-2)
• De novo mutations: Up to ~20% of cases may arise from new (de novo) mutations (review-level estimate). (gomezvirgilio2024geneticspathophysiologyand pages 1-2)

2.3 Protective factors / gene–environment interactions

No explicit protective factors or gene–environment interaction data were identifiable in the retrieved evidence excerpts.

2.4 Modifier genes (emerging)

A 2023 case-based genetic analysis suggests that additional germline variants (e.g., CHEK2) may contribute to unusually severe hemangioblastoma burden in some families, consistent with a modifier model; however, this is currently case-report level and not established for broad risk stratification. (gomezvirgilio2024geneticspathophysiologyand pages 11-13)

3. Phenotypes (clinical spectrum)

3.1 Major tumor/lesion types (with frequencies where available)

From a 2024 U.S. claims-based study (background frequencies drawn from prior literature in that paper): - CNS hemangioblastoma: occurs in ~70–80% of cases; described as “typically the first manifestation.” (jonasch2024epidemiologyandeconomic pages 1-2) - Pancreatic neuroendocrine tumors (pNET): occur in ~9–17% of cases. (jonasch2024epidemiologyandeconomic pages 1-2)

From a 2023 cohort/review focused on VHL-related pancreatic neuroendocrine tumor and diagnostic criteria: - vPNET prevalence across cohorts reported as ~5% on average, up to 17% in some cohorts. (halperin2023uniquecharacteristicsof pages 1-2)

Additional classic manifestations described across sources include retinal hemangioblastomas, clear-cell RCC, pheochromocytoma/paraganglioma (PPGL), pancreatic cystic lesions, endolymphatic sac tumors, and reproductive-tract cystadenomas. (gomezvirgilio2024geneticspathophysiologyand pages 1-2, halperin2023uniquecharacteristicsof pages 1-2)

3.2 Onset and progression (selected quantitative data)

• Review-level estimate: median age of onset 26 years. (gomezvirgilio2024geneticspathophysiologyand pages 1-2)
• Pediatric PPGL registry data: mean age at first PPGL 12.4 ± 0.41 years (range 4–18); recurrences were common (46%). (kotsis2024surveillanceinchildren pages 1-2)

3.3 Quality-of-life impacts

While the excerpts do not include validated QoL scales (e.g., SF-36/EQ-5D), the 2024 claims-based analysis and pediatric registry data emphasize high healthcare utilization, repeated procedures, and recurrence (especially PPGL), implying significant burden and care intensity. (jonasch2024epidemiologyandeconomic pages 1-2, kotsis2024surveillanceinchildren pages 1-2)

3.4 Suggested HPO terms (non-exhaustive; based on explicitly mentioned manifestations)

• CNS hemangioblastoma (HP term suggestion): Hemangioblastoma
• Retinal hemangioblastoma: Retinal hemangioblastoma / retinal capillary hemangioma
• Clear cell renal cell carcinoma: Renal cell carcinoma
• Pheochromocytoma/paraganglioma: Pheochromocytoma, Paraganglioma
• Pancreatic neuroendocrine tumor: Pancreatic neuroendocrine tumor

Note: Specific HPO IDs were not present in the retrieved excerpts; mapping to exact HP identifiers would require HPO lookup outside the retrieved papers.

4. Genetic / Molecular Information

4.1 Causal gene

• VHL (tumor suppressor); gene OMIM *608537 (alvarez2024germlinevariantsin pages 1-2).

4.2 Variant spectrum and inheritance

• Inheritance: autosomal dominant (explicitly stated in multiple sources). (gomezvirgilio2024geneticspathophysiologyand pages 1-2, alvarez2024germlinevariantsin pages 1-2)
• Variant classes: reviews describe deletions and mutations and emphasize two-hit inactivation as the tumorigenic mechanism. (gomezvirgilio2024geneticspathophysiologyand pages 1-2, gomezvirgilio2024geneticspathophysiologyand pages 11-13)

4.3 Penetrance and expressivity

• Review-level estimate: ~97% penetrance by age 65. (gomezvirgilio2024geneticspathophysiologyand pages 1-2)

4.4 Somatic vs germline

• Germline VHL alteration defines inherited VHL disease; tumors typically arise after somatic inactivation of the remaining allele (loss of heterozygosity concept is discussed in mechanistic reviews). (ohh2022hypoxiainduciblefactorunderlies pages 1-2)

5. Environmental Information

No clear environmental/lifestyle/infectious triggers were identified in the retrieved evidence excerpts as causal or modifying factors for VHL disease.

6. Mechanism / Pathophysiology (causal chains; upstream→downstream)

6.1 Canonical pVHL–HIF axis (core mechanism)

Upstream trigger: germline VHL loss-of-function variant + somatic “second hit” in susceptible cells (tumor suppressor model). (kaelin2022vonhippel–lindaudisease pages 1-2, ohh2022hypoxiainduciblefactorunderlies pages 1-2)

Core molecular mechanism: pVHL is the substrate-recognition subunit of a Cullin2-based E3 ubiquitin ligase that targets hydroxylated HIFα for proteasomal degradation in oxygen-dependent fashion; VHL loss stabilizes HIFα, especially HIF2α. (kaelin2022vonhippel–lindaudisease pages 1-2, gomezvirgilio2024geneticspathophysiologyand pages 11-13)

Downstream consequences: stabilized HIFα translocates to the nucleus, dimerizes with HIFβ, and activates gene expression programs promoting angiogenesis, altered metabolism, and tumor growth, helping explain the vascular nature of many VHL-associated tumors. (gomezvirgilio2024geneticspathophysiologyand pages 11-13)

Therapeutic connection: VEGF pathway inhibitors are a mainstay of ccRCC treatment; an allosteric HIF2 inhibitor (belzutifan) is approved for VHL-associated ccRCC based on this mechanistic dependency. (kaelin2022vonhippel–lindaudisease pages 1-2)

6.2 mTORC1 activation via pVHL loss (HIF-independent link)

A review and supporting primary data describe a HIF-independent mechanism: VHL can repress RAPTOR and thereby inhibit mTORC1 signaling; loss of VHL derepresses mTORC1, which is frequently hyperactivated in ccRCC. (ganner2021vhlsuppressesraptor pages 1-2, gomezvirgilio2024geneticspathophysiologyand pages 11-13)

6.3 2024 mechanistic development: VHL control of m6A RNA methylation (HIF-independent)

A 2024 JCI mechanistic study reports that VHL binds and promotes METTL3/METTL14 complex formation; VHL depletion suppresses m6A modification. The study identifies PIK3R3 as a VHL–m6A-regulated target whose mRNA stability is controlled in an m6A-dependent but HIF-independent manner; PIK3R3 suppresses renal tumor growth by restraining PI3K/AKT signaling. (zhang2024vonhippellindau pages 1-2)

6.4 Suggested pathway/ontology terms (based on mechanisms described)

• GO Biological Process (suggestions): hypoxia response / oxygen sensing; ubiquitin-dependent protein catabolic process; regulation of angiogenesis; regulation of mTOR signaling; RNA methylation (m6A); PI3K/AKT signaling regulation.
• Cell types (CL suggestions): renal tubular epithelial cells; chromaffin cells (for PPGL); retinal vascular-associated cells; CNS vascular-associated stromal cells.

Exact GO/CL identifiers were not present in the retrieved excerpts and would require ontology lookup.

7. Anatomical Structures Affected (multi-organ)

Across sources, VHL disease affects: - CNS (brain/spinal cord): CNS hemangioblastomas (jonasch2024epidemiologyandeconomic pages 1-2) - Eye/retina: retinal hemangioblastomas (halperin2023uniquecharacteristicsof pages 1-2) - Kidney: cysts and clear-cell RCC (halperin2023uniquecharacteristicsof pages 1-2) - Pancreas: pancreatic lesions including pNETs and serous cystadenomas (else2024belzutifanforvon pages 5-6) - Adrenal/paraganglia: pheochromocytoma/paraganglioma (halperin2023uniquecharacteristicsof pages 1-2)

8. Temporal Development (onset, course)

• Manifestations may begin in childhood/adolescence (e.g., PPGL, CNS lesions), with progressive emergence of additional lesions over time and frequent need for serial interventions. (kotsis2024surveillanceinchildren pages 1-2, knoblauch2024screeningandsurveillance pages 1-2)

9. Inheritance and Population

9.1 Epidemiology (recent data and statistics)

Disease-level prevalence estimates (review): prevalence described as approximately 1 in 36,000 worldwide in a 2024 review; another estimate range given is 1 in 39,000 to 1 in 91,000. (gomezvirgilio2024geneticspathophysiologyand pages 1-2, gomezvirgilio2024geneticspathophysiologyand pages 22-24)

U.S. real-world prevalence for selected VHL manifestations (claims-based, 2019): - VHL-associated CNS hemangioblastoma: 1.12 per 100,000 (estimated 3,678 patients) - VHL-associated pancreatic NET: 0.12 per 100,000 (estimated 389 patients) (jonasch2024epidemiologyandeconomic pages 1-2)

9.2 Penetrance

• ~97% by age 65 (review-level). (gomezvirgilio2024geneticspathophysiologyand pages 1-2)

10. Diagnostics

10.1 Clinical diagnostic criteria (recent comparative analysis)

A 2023 study highlights that VHL can be clinically diagnosed via differing criteria sets (International vs Danish) and argues for genetic testing to improve diagnostic accuracy, especially in visceral-only presentations. In their cohort, vPNET patients meeting International Criteria had 90% germline VHL PV and 70% family history vs 20% and 10% in Danish-only cases. (halperin2023uniquecharacteristicsof pages 1-2)

10.2 Imaging and screening/surveillance (recent consensus and cohorts)

Updated pediatric/adolescent surveillance recommendations (2023 AACR workshop update summarized in 2025)

• Blood pressure: at all visits starting at 2 years (rednam2025updateonsurveillance pages 8-10)
• PPGL biochemistry: annual fractionated metanephrines starting at 5 years (plasma or 24-hour urine) (rednam2025updateonsurveillance pages 8-10, rednam2025updateonsurveillance pages 11-13)
• Abdominal MRI (RCC/PanNET): contrast MRI every 2 years starting at 15 years (rednam2025updateonsurveillance pages 11-13, rednam2025updateonsurveillance pages 13-13)
• Brain/spine MRI: recommendations vary by consensus group; once started, biennial imaging is consistently supported (rednam2025updateonsurveillance pages 8-10)
• Ophthalmology: at least annual examinations from diagnosis; in younger children, as often as every 6 months may be considered (rednam2025updateonsurveillance pages 8-10)
• Audiology: strategies differ (e.g., biennial from 11 years vs annual age 5–13 then biennial) (rednam2025updateonsurveillance pages 8-10)

2024 pediatric CNS cohort evidence

A 2024 pediatric cohort recommends starting CNS MRI at 12 years with intervals every (1–)2 years depending on involvement; truncating variants showed higher manifestation and surgery rates (HR 3.7 and 3.3). (knoblauch2024screeningandsurveillance pages 1-2)

10.3 Biomarkers/labs

The surveillance update explicitly uses fractionated metanephrines (plasma or urine) as screening biochemistry for PPGL beginning at age 5. (rednam2025updateonsurveillance pages 11-13)

11. Outcome / Prognosis

• A 2023 clinical/review source notes leading causes of death as CNS hemangioblastoma followed by RCC (cohort/review-level statement). (halperin2023uniquecharacteristicsof pages 1-2)
• The 2024 U.S. claims study demonstrates substantial healthcare utilization and higher annual costs relative to controls, reflecting chronic morbidity and repeated interventions. (jonasch2024epidemiologyandeconomic pages 1-2)

Survival curves and life expectancy estimates were not present in the retrieved excerpts.

12. Treatment

12.1 Standard interventions (real-world implementation)

For selected lesion types, management commonly involves surveillance with intervention thresholds: - CNS hemangioblastoma: active surveillance for asymptomatic lesions; surgery for symptomatic or CSF-obstructing lesions (as summarized in the 2024 claims-based study background). (jonasch2024epidemiologyandeconomic pages 1-2) - pNET: lesions >2–3 cm recommended for surgical removal (background statement in 2024 claims-based study). (jonasch2024epidemiologyandeconomic pages 1-2)

12.2 Targeted systemic therapy — HIF-2α inhibition (belzutifan)

Mechanistic rationale: HIF2 drives VHL-defective ccRCC growth; HIF2 inhibition is mechanistically aligned with the central VHL pathway. (kaelin2022vonhippel–lindaudisease pages 1-2)

Key 2024 clinical trial evidence (pancreatic lesions, LITESPARK-004): - Study: single-arm phase 2 LITESPARK-004 (NCT03401788), belzutifan 120 mg once daily. (else2024belzutifanforvon pages 5-6) - Pancreatic lesion population: 61/61 (100%) had ≥1 pancreatic lesion; 22/61 (36%) had measurable pNET at baseline; median follow-up 37.8 months. (else2024belzutifanforvon pages 5-6) - Objective response rate (ORR): pancreatic lesions 84% (51/61) with 17 complete responses; pNETs 91% (20/22) with 7 complete responses. (else2024belzutifanforvon pages 5-6) - Safety: 18% had ≥1 grade 3 treatment-related AE; no grade 4/5 treatment-related AEs reported. (else2024belzutifanforvon pages 5-6)

Real-world relevance: A 2024 U.S. claims analysis highlights the high costs of surgery for VHL-CNS hemangioblastoma and VHL-pNET, providing a health-economic rationale for effective medical therapies that could reduce surgical frequency/burden. (jonasch2024epidemiologyandeconomic pages 1-2)

12.3 Suggested treatment ontology terms

• CHEBI (example): belzutifan (small-molecule HIF-2α inhibitor; CHEBI ID not provided in excerpts)
• MAXO (suggestions): MRI surveillance; surgical resection; tumor ablation; targeted molecular therapy (HIF-2α inhibition); biochemical screening (metanephrines).

13. Prevention

13.1 Primary prevention

Not applicable in the classic infectious/toxic exposure sense; VHL is a genetic condition.

13.2 Secondary prevention (surveillance as prevention of complications)

The updated pediatric/adolescent surveillance framework (blood pressure, metanephrines, eye exams, MRIs) is a central preventive strategy intended to enable early detection and timely intervention. (rednam2025updateonsurveillance pages 8-10, rednam2025updateonsurveillance pages 11-13, rednam2025updateonsurveillance pages 13-13, knoblauch2024screeningandsurveillance pages 1-2)

14. Other species / natural disease

No naturally occurring non-human VHL disease analogs were identified in the retrieved excerpts.

15. Model organisms

Evidence excerpts supporting models/mechanistic conservation include: - C. elegans: loss of vhl-1 increased mTORC1 activity, supporting evolutionary conservation of VHL–mTORC1 regulation. (ganner2021vhlsuppressesraptor pages 1-2)

Detailed mouse/zebrafish models for VHL-associated tumor phenotypes were not available in the retrieved evidence excerpts used for citations in this report.

Recent developments (2023–2024 highlights)

1. Claims-based U.S. epidemiology and economic burden (Feb 2024): prevalence estimates for VHL-CNS hemangioblastoma and VHL-pNET in 2019 and quantification of excess annual costs (+$49,645 and +$56,580, respectively). (jonasch2024epidemiologyandeconomic pages 1-2)
2. Belzutifan efficacy in VHL pancreatic lesions (Feb 2024): high ORR/CR rates in pancreatic lesions and measurable pNETs with long follow-up and manageable safety. (else2024belzutifanforvon pages 5-6)
3. HIF-independent pVHL mechanism via m6A (Apr 2024): VHL regulation of METTL3/METTL14 complex formation and m6A-dependent stabilization of PIK3R3 as a brake on PI3K/AKT-driven tumorigenesis. (zhang2024vonhippellindau pages 1-2)

Embedded quantitative summary table

Table: This table compiles the key 2023-2025 quantitative findings and surveillance recommendations extracted so far for von Hippel–Lindau disease. It emphasizes epidemiology, phenotype frequency, pediatric surveillance timing, and belzutifan phase 2 efficacy data relevant for a disease knowledge base.

Notes on evidence limitations (for knowledge base curation)

• Many requested ontology IDs (MONDO, MeSH, Orphanet) and some phenotype-specific HPO IDs were not explicitly present in the accessible excerpts and therefore could not be safely asserted here.
• Survival/life expectancy statistics and standardized QoL instrument outcomes were not present in the retrieved excerpts.
• While belzutifan and surveillance are strongly supported with recent data, quantitative outcomes for many local interventions (e.g., stereotactic radiosurgery, ablation modalities) were not available in the extracted evidence.

References

1. (gomezvirgilio2024geneticspathophysiologyand pages 1-2): Laura Gómez-Virgilio, Mireya Velazquez-Paniagua, Lucero Cuazozon-Ferrer, Maria-del-Carmen Silva-Lucero, Andres-Ivan Gutierrez-Malacara, Juan-Ramón Padilla-Mendoza, Jessica Borbolla-Vázquez, Job-Alí Díaz-Hernández, Fausto-Alejandro Jiménez-Orozco, and Maria-del-Carmen Cardenas-Aguayo. Genetics, pathophysiology, and current challenges in von hippel–lindau disease therapeutics. Diagnostics, 14:1909, Aug 2024. URL: https://doi.org/10.3390/diagnostics14171909, doi:10.3390/diagnostics14171909. This article has 8 citations.

2. (alvarez2024germlinevariantsin pages 1-2): Antonio Alejandro Esperón Álvarez, Inés Virginia Noa Hechavarría, Ixchel López Reyes, and Teresa Collazo Mesa. Germline variants in the von hippel-lindau tumor suppressor gene in cuban patients. Egyptian Journal of Medical Human Genetics, Mar 2024. URL: https://doi.org/10.1186/s43042-024-00506-5, doi:10.1186/s43042-024-00506-5. This article has 0 citations and is from a peer-reviewed journal.

3. (kaelin2022vonhippel–lindaudisease pages 1-2): William G. Kaelin. Von hippel–lindau disease: insights into oxygen sensing, protein degradation, and cancer. The Journal of Clinical Investigation, Sep 2022. URL: https://doi.org/10.1172/jci162480, doi:10.1172/jci162480. This article has 151 citations.

4. (jonasch2024epidemiologyandeconomic pages 1-2): Eric Jonasch, Yan Song, Jonathan Freimark, Richard Berman, Ha Nguyen, James Signorovitch, and Murali Sundaram. Epidemiology and economic burden of von hippel-lindau disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the united states. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03060-w, doi:10.1186/s13023-024-03060-w. This article has 7 citations and is from a peer-reviewed journal.

5. (else2024belzutifanforvon pages 5-6): Tobias Else, Eric Jonasch, Othon Iliopoulos, Kathryn E. Beckermann, Vivek Narayan, Benjamin L. Maughan, Stephane Oudard, Jodi K. Maranchie, Ane B. Iversen, Cynthia M. Goldberg, Wei Fu, Rodolfo F. Perini, Yanfang Liu, W. Marston Linehan, and Ramaprasad Srinivasan. Belzutifan for von hippel-lindau disease: pancreatic lesion population of the phase 2 litespark-004 study. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:1750-1757, Feb 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-2592, doi:10.1158/1078-0432.ccr-23-2592. This article has 26 citations.

6. (zhang2024vonhippellindau pages 1-2): Cheng Zhang, Miaomiao Yu, Austin J. Hepperla, Zhao Zhang, Rishi Raj, Hua Zhong, Jin Zhou, Lianxin Hu, Jun Fang, Hongyi Liu, Qian Liang, Liwei Jia, Chengheng Liao, Sichuan Xi, Jeremy M. Simon, Kexin Xu, Zhijie Liu, Yunsun Nam, Payal Kapur, and Qing Zhang. Von hippel lindau tumor suppressor controls m6a-dependent gene expression in renal tumorigenesis. The Journal of Clinical Investigation, Apr 2024. URL: https://doi.org/10.1172/jci175703, doi:10.1172/jci175703. This article has 13 citations.

7. (hochberg2024isthetrinetx pages 1-2): Aaron R. Hochberg, Patrick T. Gomella, Brian Im, Anushka Ghosh, Sohan Shah, Rasheed A.M. Thompson, Kevin K. Zarrabi, Mihir S. Shah, J. Ryan Mark, Joseph K. Izes, Costas D. Lallas, Leonard G. Gomella, and Adam R. Metwalli. Is the trinetx database a good tool for investigation of real-world management of von hippel–lindau? Journal of Kidney Cancer and VHL, 11:28-38, Dec 2024. URL: https://doi.org/10.15586/jkcvhl.v11i4.324, doi:10.15586/jkcvhl.v11i4.324. This article has 4 citations.

8. (gomezvirgilio2024geneticspathophysiologyand pages 11-13): Laura Gómez-Virgilio, Mireya Velazquez-Paniagua, Lucero Cuazozon-Ferrer, Maria-del-Carmen Silva-Lucero, Andres-Ivan Gutierrez-Malacara, Juan-Ramón Padilla-Mendoza, Jessica Borbolla-Vázquez, Job-Alí Díaz-Hernández, Fausto-Alejandro Jiménez-Orozco, and Maria-del-Carmen Cardenas-Aguayo. Genetics, pathophysiology, and current challenges in von hippel–lindau disease therapeutics. Diagnostics, 14:1909, Aug 2024. URL: https://doi.org/10.3390/diagnostics14171909, doi:10.3390/diagnostics14171909. This article has 8 citations.

9. (halperin2023uniquecharacteristicsof pages 1-2): Reut Halperin, Liat Arnon, Yehudit Eden-Friedman, and Amit Tirosh. Unique characteristics of patients with von hippel–lindau disease defined by various diagnostic criteria. Cancers, 15:1657, Mar 2023. URL: https://doi.org/10.3390/cancers15061657, doi:10.3390/cancers15061657. This article has 9 citations.

10. (kotsis2024surveillanceinchildren pages 1-2): Fruzsina Kotsis, Marina Kunstreich, Antje Redlich, Kilian Rhein, Athina Ganner, Gerd Walz, Michaela Kuhlen, and Elke Neumann-Haefelin. Surveillance in children and adolescents with von hippel-lindau (vhl)-related pheochromocytomas and paragangliomas: a survey of met and freiburg-vhl registries in germany. Journal of Kidney Cancer, 11:15-27, Nov 2024. URL: https://doi.org/10.15586/jkcvhl.v11i4.362, doi:10.15586/jkcvhl.v11i4.362. This article has 0 citations.

11. (ohh2022hypoxiainduciblefactorunderlies pages 1-2): Michael Ohh, Cassandra C Taber, Fraser G Ferens, and Daniel Tarade. Hypoxia-inducible factor underlies von hippel-lindau disease stigmata. eLife, Aug 2022. URL: https://doi.org/10.7554/elife.80774, doi:10.7554/elife.80774. This article has 34 citations and is from a domain leading peer-reviewed journal.

12. (ganner2021vhlsuppressesraptor pages 1-2): Athina Ganner, Christina Gehrke, Marinella Klein, Lena Thegtmeier, Tanja Matulenski, Laura Wingendorf, Lu Wang, Felicitas Pilz, Lars Greidl, Lisa Meid, Fruzsina Kotsis, Gerd Walz, Ian J. Frew, and Elke Neumann-Haefelin. Vhl suppresses raptor and inhibits mtorc1 signaling in clear cell renal cell carcinoma. Scientific Reports, Jul 2021. URL: https://doi.org/10.1038/s41598-021-94132-5, doi:10.1038/s41598-021-94132-5. This article has 40 citations and is from a peer-reviewed journal.

13. (knoblauch2024screeningandsurveillance pages 1-2): Anna Laura Knoblauch, Bianca-Ioana Blaß, C. Steiert, N. Neidert, A. Puzik, E. Neumann-Haefelin, A. Ganner, F. Kotsis, T. Schäfer, H.P.H. Neumann, S. Elsheikh, J. Beck, and Jan-Helge Klingler. Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with von hippel-lindau disease. Journal of Neuro-Oncology, 168:537-545, Apr 2024. URL: https://doi.org/10.1007/s11060-024-04676-5, doi:10.1007/s11060-024-04676-5. This article has 5 citations and is from a peer-reviewed journal.

14. (gomezvirgilio2024geneticspathophysiologyand pages 22-24): Laura Gómez-Virgilio, Mireya Velazquez-Paniagua, Lucero Cuazozon-Ferrer, Maria-del-Carmen Silva-Lucero, Andres-Ivan Gutierrez-Malacara, Juan-Ramón Padilla-Mendoza, Jessica Borbolla-Vázquez, Job-Alí Díaz-Hernández, Fausto-Alejandro Jiménez-Orozco, and Maria-del-Carmen Cardenas-Aguayo. Genetics, pathophysiology, and current challenges in von hippel–lindau disease therapeutics. Diagnostics, 14:1909, Aug 2024. URL: https://doi.org/10.3390/diagnostics14171909, doi:10.3390/diagnostics14171909. This article has 8 citations.

15. (rednam2025updateonsurveillance pages 8-10): Surya P. Rednam, Kerri D. Becktell, Anita Villani, Garrett M. Brodeur, Lisa J. States, Andrea S. Doria, Junne Kamihara, Kami Wolfe Schneider, Stephan D. Voss, Elysa Widjaja, Kristin Zelley, Yoshiko Nakano, Kristian W. Pajtler, Maria Isabel Achatz, David Malkin, Lisa R. Diller, Bailey Gallinger, Chieko Tamura, and Jonathan D. Wasserman. Update on surveillance in von hippel-lindau disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 31:2271-2277, Apr 2025. URL: https://doi.org/10.1158/1078-0432.ccr-24-3525, doi:10.1158/1078-0432.ccr-24-3525. This article has 8 citations.

16. (rednam2025updateonsurveillance pages 11-13): Surya P. Rednam, Kerri D. Becktell, Anita Villani, Garrett M. Brodeur, Lisa J. States, Andrea S. Doria, Junne Kamihara, Kami Wolfe Schneider, Stephan D. Voss, Elysa Widjaja, Kristin Zelley, Yoshiko Nakano, Kristian W. Pajtler, Maria Isabel Achatz, David Malkin, Lisa R. Diller, Bailey Gallinger, Chieko Tamura, and Jonathan D. Wasserman. Update on surveillance in von hippel-lindau disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 31:2271-2277, Apr 2025. URL: https://doi.org/10.1158/1078-0432.ccr-24-3525, doi:10.1158/1078-0432.ccr-24-3525. This article has 8 citations.

17. (rednam2025updateonsurveillance pages 13-13): Surya P. Rednam, Kerri D. Becktell, Anita Villani, Garrett M. Brodeur, Lisa J. States, Andrea S. Doria, Junne Kamihara, Kami Wolfe Schneider, Stephan D. Voss, Elysa Widjaja, Kristin Zelley, Yoshiko Nakano, Kristian W. Pajtler, Maria Isabel Achatz, David Malkin, Lisa R. Diller, Bailey Gallinger, Chieko Tamura, and Jonathan D. Wasserman. Update on surveillance in von hippel-lindau disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 31:2271-2277, Apr 2025. URL: https://doi.org/10.1158/1078-0432.ccr-24-3525, doi:10.1158/1078-0432.ccr-24-3525. This article has 8 citations.